The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16/18-infection in cervical cancer cells

• Published in: Infectious agents and cancer 2021-12, Vol.16 (1), p.71-71, Article 71
• Main Authors: Wang, Yinghui, Xie, Yihang, Sun, Boxuan, Guo, Yuwei, Song, Ling, Mohammednur, Dawit Eman, Zhao, Chunyan
• Format: Article
• Language: English
• Subjects: Analysis; Autophagy; Biotechnology; Cancer cells; Cervical cancer; Cervix; Degradation; E6AP; Genetic research; Health aspects; HPV; Human papillomavirus; Immunoprecipitation; Infection; Infections; Monoclonal antibodies; p53 Protein; Papillomaviridae; Papillomavirus infections; Polyclonal antibodies; Proteasomes; Proteins; Proteolysis; Rap1GAP; Rapamycin; siRNA; Tumor proteins; Tumor suppressor genes; Tumorigenesis; Ubiquitin; Ubiquitin-proteasome pathway; Ubiquitination; Western blotting
• ISSN: 1750-9378; 1750-9378
• DOI: 10.1186/s13027-021-00409-9

Cervical cancers are closely associated with persistent high-risk human papillomaviruses (HR HPV) infection. The main mechanism involves the targeting of tumor suppressors, such as p53 and pRB, for degradation by HR HPV-encoded oncoproteins, thereby leading to tumorigenesis. Rap1GAP, a tumor suppressor gene, is down-regulated in many cancers. Previous studies have revealed that down-regulation of Rap1GAP is correlated with HPV16/18 infection in cervical cancer. However, the molecular mechanism remains unclear. In this study, we aimed to address the degradation pathway of Rap1GAP in HPV-positive cervical cancer cells. HPV-positive (HeLa and SiHa) and negative (C33A) cervical cancer cells were used to analyze the pathways of Rap1GAP degradation. MG132 (carbobenzoxy-leucyl-leucyl-leucine) was used to inhibit protein degradation by proteasome. Co-immunoprecipitation (co-IP) was used to detect the interaction between Rap1GAP and E6AP. siRNA for E6AP was used to silence the expression of E6AP. Rapamycin was used to induce cell autophagy. Western blotting was used to check the levels of proteins. Following treatment with MG132, the levels of Rap1GAP were increased in the HR HPV-positive HeLa and SiHa cells, but not in the HPV-negative C33A cells. Co-immunoprecipitation assay revealed ubiquitinated Rap1GAP protein in HeLa and SiHa cells, but not in C33A cells. E6-associated protein (E6AP) mediated the ubiquitination of Rap1GAP by binding to it in HeLa and SiHa cells, but not in C33A cells. However, the levels of Rap1GAP were decreased in HeLa and SiHa cells after knocking down E6AP by siRNA. Silencing of E6AP did not affect the levels of Rap1GAP in C33A cells. Autophagy marker p62 was decreased and LC3 II/LC3 I was increased after knocking down E6AP in HeLa cells, but not in C33A cells. The levels of Rap1GAP were decreased after treating the cells with rapamycin to induce cell autophagy in HeLa and C33A cells. Rap1GAP may be degraded by autophagy in cervical cancer cells, but HPV infection can switch the degradation pathway from autophagy to E6AP-mediated ubiquitin-proteasome degradation. E6AP may be a key component of the switch.